HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently developed HIV-related KS (cases), and among 108 matched HIV/KSHV co-infected controls who did not develop KS. Throughout the six years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls (p<0.0001) and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls, compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the pathogenesis of HIV-related KS in this setting. This article is protected by copyright. All rights reserved.
|Number of pages||9|
|Journal||International Journal of Cancer|
|Early online date||28 Nov 2014|
|Publication status||E-pub ahead of print - 28 Nov 2014|